Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 74 (8), 759-64

Current Status of Iron Overload and Chelation With Deferasirox

Affiliations
Review

Current Status of Iron Overload and Chelation With Deferasirox

V P Choudhry et al. Indian J Pediatr.

Abstract

A large number of complications in thalassemia major are due mainly to iron overload. Deferoxamine in iron-overloaded patients has established that chelation therapy, when given at an adequate dose, reduces iron-related complications. Parenteral administration and the daily nuisance of an infusion pump hinder the optimal compliance. Deferiprone is moderately effective oral iron chelator. Arthralgia and cytopenias constitute the main side effects. Deferasirox is a new orally effective iron chelator which has been shown to be non-inferior to deferoxamine in clinical trials. Further clinical trials especially in Indian children will tell if it stands the test of time.

Similar articles

See all similar articles

Cited by 4 PubMed Central articles

References

    1. N Engl J Med. 1982 Dec 30;307(27):1671-5 - PubMed
    1. Blood. 2004 Mar 1;103(5):1934-6 - PubMed
    1. Annu Rev Med. 2005;56:157-71 - PubMed
    1. Blood. 2006 May 1;107(9):3455-62 - PubMed
    1. Haematologica. 2006 Jun;91(6 Suppl):ELT04 - PubMed

MeSH terms

LinkOut - more resources

Feedback